Key result
Myeloid RGS2 deletion fails to worsen angiotensin II-induced hypertension or end-organ damage in mice.
Why the study?
While evidence supports a key role for RGS2 in vascular tissue, its role in immune cells remained underexplored.
Does genetic ablation of RGS2 in myeloid cells amplify angiotensin II-induced hypertension and exacerbating inflammatory response and organ damage in mice?
Does genetic ablation of RGS2 in myeloid cells amplify angiotensin II-induced hypertension and exacerbating inflammatory response and organ damage in mice?
p-value: p=0.89
Genetic deletion of RGS2 in myeloid cells does not alter blood pressure elevation or end-organ damage in response to chronic angiotensin II infusion, suggesting myeloid RGS2 is not a critical driver of these hypertensive pathologies in mice.
Does not support myeloid RGS2 targeting in hypertension; leaves open cell-type-specific roles in cardiovascular pathology.
The role of the immune system in the development of hypertension is well‐established. Recent studies revealed the critical role of G‐protein‐coupled receptor signaling, particularly angiotensin II (Ang II) type 1 receptor (AT1R), in immune cell function. Regulator of G‐protein signaling (RGS) proteins are critical players in terminating G‐protein‐coupled receptor signaling, with RGS2 being particularly interesting because it limits signaling downstream of AT1R. Importantly, RGS2 is highly expressed in myeloid immune cells. Global RGS2 deletion results in elevated blood pressure and Ang II‐dependent vascular hypercontractility. While evidence supports a key role for RGS2 in vascular tissue, its role in immune cells remains underexplored. Herein, we hypothesized that genetic ablation of RGS2 in myeloid cells would amplify Ang II signaling, thereby exacerbating the inflammatory response to Ang II. To test this hypothesis, we employed a conditional myeloid‐specific RGS2 knockout mouse model (RGS2 LysM‐KO ) subjected to chronic Ang II treatment. Contrary to our expectations, both Control and RGS2 LysM‐KO exhibited comparable changes in blood pressure, cardiac hypertrophy, albuminuria, renal tubular injury markers, vascular dysfunction, and inflammatory profiles in response to Ang II. Altogether, we conclude that myeloid RGS2 does not significantly affect blood pressure nor modulate renal injury or vascular dysfunction effects of Ang II.
No takes yet. Share an insight, caveat, or question.
Nakagawa et al. (2026) studied Angiotensin II-induced hypertension (n=38). Conditional myeloid-specific RGS2 knockout (RGS2 LysM-KO) vs. RGS2 LysM-WT (Control) was evaluated on Systolic blood pressure under Angiotensin II treatment (p=0.89). Myeloid-specific deletion of RGS2 did not significantly exacerbate blood pressure elevation, cardiac hypertrophy, renal injury, or vascular dysfunction in mice subjected to chronic angiotensin II infusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: